|+1 404 474 4654|
|+1 888 205 9894 (TF)|
Nuclear Factor of kappa Light Polypeptide Gene Enhancer in B-Cells Inhibitor, alpha (NFKBIA) (pSer320) antibody
|Synonyms||IKBA, MAD-3, NFKBI|
Alternatives Western Blotting (WB), Immunocytochemistry (ICC), Immunoprecipitation (IP)
|5 references available|
|Price||507.14 $ Plus shipping costs $45.00|
|Availability||Will be delivered in 2 to 3 Business Days|
|Characteristics||Rabbit Monoclonal IgG|
|Specificity||A phospho specific peptide corresponding to residues surrounding Serine 32 of human IkappaB-alpha was used as an immunogen.|
|Molecular Weight||40 kDA|
Background: The NF-kappaB/Rel transcription factors are present in the cytosol in an inactive state, complexed with the inhibitory IkappaB-alpha protein (1-5). In response to many different NF-kappaB-inducing agents including T-cell mitogens, proinflammatory cytokines, and viral transactivators, the inhibitory IkappaB-alpha is rapidly phosphorylated and degraded (2). Phosphorylation of IkappaB-alpha at Ser32 and Ser36 has been shown to stimulate conjugation with ubiquitin and subsequent degradation of IkappaB-alpha (3). Activation of NF-kappaB can also be achieved after tyrosine phosphorylation of IkappaBalpha at tyrosine 42, an event that also ultimately leads to the dissociation of NF-kappaB and IkappaBalpha (4). Phosphorylation of IkappaB-alpha at Ser32 and Tyr42 is critical for activation of NF-kappaB, which then translocates to the nucleus and induces transcription of genes that protect organism (1-5).
|Application Notes||The suggested dilution is: WB: ~~ 1:100010000 IP: ~~ 1:10~100 ICC: ~~ 1:50~100|
|Buffer||50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.|
|Storage||IkappaB-alpha Antibody Phospho (S32) can be stored at -20°C for up to 12 months from time of receipt.|
|Research Area||Ubiquitin-related antibodies, Phospho-specific antibodies, Protein Modifications, Cell Structure|
|Restrictions||For Research Use only|
Brockman, Scherer, McKinsey et al.: "Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation." in: Molecular and cellular biology, Vol. 15, Issue 5, pp. 2809-18, 1995 (PubMed).
Traenckner, Pahl, Henkel et al.: "Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli." in: The EMBO journal, Vol. 14, Issue 12, pp. 2876-83, 1995 (PubMed).
Brown, Gerstberger, Carlson et al.: "Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation." in: Science (New York, N.Y.), Vol. 267, Issue 5203, pp. 1485-8, 1995 (PubMed).
Chen, Parent, Maniatis: "Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity." in: Cell, Vol. 84, Issue 6, pp. 853-62, 1996 (PubMed).
Witherow, Garrison, Miller et al.: "beta-Arrestin inhibits NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, Issue 23, pp. 8603-7, 2004 (PubMed).